河北正定县1986—1996年出生人群乙肝疫苗基础免疫21~32年后加强免疫效果分析
该研究纳入河北省正定县1986—1996年出生、完成血源乙肝疫苗基础免疫21~32年、无加强免疫史且抗-HBs<10 mIU/ml的322名对象,随机接种1剂20 μg啤酒酵母乙肝疫苗或CHO乙肝疫苗。加强后30天抗-HBs阳转率为82.61%,GMC为131.63±12.94 mIU/ml;加强前抗-HBs水平和疫苗种类与免疫应答相关。
要点
- 基础免疫21~32年后加强1剂乙肝疫苗总体阳转率82.61%,免疫应答良好。
- 加强前抗-HBs 2.5~10 mIU/ml者阳转率99.06%,显著高于<2.5 mIU/ml者的74.54%。
- CHO乙肝疫苗加强后阳转率87.13%,高于啤酒酵母乙肝疫苗的77.48%。
核心结论
- 研究对象接种1剂乙型肝炎疫苗有良好的免疫应答;加强免疫前抗-HBs水平和加强用疫苗种类是免疫应答的相关因素。
研究设计与样本
- 2017年8月至2018年2月选取正定县1986—1996年出生、完成血源HepB基础免疫且无加强免疫史、HBsAg和抗-HBc均阴性、抗-HBs<10 mIU/ml并完成加强免疫且有实验室结果者共322名。
- 采用简单随机分组方法将322名研究对象随机分为2组,分别接种1剂20 μg啤酒酵母HepB(151名)和基因重组HepB(CHO,171名)。
- 免疫后30 d采集静脉血5 ml,定量检测抗-HBs的GMC,采用多元线性回归和多因素logistic回归模型分析相关因素。
主要发现
- 研究对象抗-HBs阳转率为82.61%(266名),GMC为(131.63±12.94)mIU/ml。
- 加强免疫前抗-HBs<2.5和2.5~10 mIU/ml组加强免疫后抗-HBs阳转率分别为74.54%(161名)和99.06%(105名)(P<0.001)。
- 加强1剂HepB(CHO)后抗-HBs阳转率高于加强1剂HepB(酵母),分别为87.13%(149名)和77.48%(117名)(P=0.023)。
- 与接种HepB(酵母)相比,接种HepB(CHO)是加强免疫后抗体阳转的相关因素,OR(95%CI)值为1.91(1.02~3.56)(P=0.042)。
- 与加强免疫前抗-HBs<2.5 mIU/ml相比,加强前抗体水平2.5~10 mIU/ml是加强免疫后抗体阳转的相关因素,OR(95%CI)值为36.15(4.91~266.02)(P<0.001)。
临床怎么用
- 对完成乙肝疫苗基础免疫21~32年、抗-HBs<10 mIU/ml且HBsAg和抗-HBc阴性者,加强1剂20 μg乙肝疫苗可获得良好免疫应答。
- 加强前抗-HBs水平2.5~10 mIU/ml者加强后阳转率更高,提示加强前抗体水平有助于预判免疫应答。
- CHO乙肝疫苗加强后抗体阳转率高于啤酒酵母乙肝疫苗,选择加强疫苗种类时可参考该结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: Aanalysis the effect of booster one dose of hepatitis B vaccine after 21-32 years of primary immunization in Zhengding Country of Hebei Province. Methods: A total of 322 participants who were born between 1986 and 1996, received a full course of primary vaccination with plasma-derived hepatitis B vaccine (HepB), had no experience with booster vaccination, were HBsAg, anti-HBcnegative, had anti-HBs<10 mIU/ml, completed the booster and had laboratory results were enrolled between August 2017 to February 2018. A simple random method was uesd to randomly assigned 322 subjects to two groups, receiving a booster dose of HepB derived from either Saccharomyces cerevisiae [HepB (SC), (151 cases)] or Chinese hamster ovary-derived HepB [HepB (CHO), (171 cases)], the dose was 20 μg. Blood samples were collected 30 days after boosting and quantitatively tested for the geometric mean concentration (GMC) of anti-HBs to assess immunological effect. The related influencing factors of GMC and seroconversion rates of anti-HBs were analyzed by multiple linear regression and multivariate logistic regression models. Results: The 266 subjects (82.61%) had anti-HBs≥ 10 mIU/ml, and GMC was (131.63±12.94) mIU/ml.The seroconversion rates of anti-HBs in the anti-HBs<2.5 mIU/ml group and 2.5-10 mIU/ml group were 74.54% (161 cases) and 99.06% (105 cases), respectively (P<0.001).The seroconversion rates of anti-HBs after one dose of HepB (CHO) was higher than that of one dose of HepB (SC), the seroconversion rates were 87.13% (149 cases) and 77.48% (117 cases), respectively (P=0.023). Participants boostered with HepB (CHO) was the factor influencing the effect of strengthening immunization compared with boostered with HepB (SC), and OR (95%CI) was 1.91 (1.02-3.56) (P=0.042).Compared with anti-HBs<2.5 mIU/ml, prebooster anti-HBs was between 2.5 mIU/ml and 10 mIU/ml was the related factor of seroconversion rates of anti-HBs after booster immunization, and OR (95%CI) was 36.15 (4.91-266.02) (P<0.001). Conclusion: Participants boostered withone dose of HepB had a good immune response. Pre-booster anti-HBs concentration and a variety of vaccine were related factors of immune response. 目的: 分析河北省正定县人群乙型肝炎疫苗(HepB)基础免疫21~32年后加强免疫的效果。 方法: 2017年8月至2018年2月选取正定县1986—1996年出生、完成血源HepB基础免疫且无加强免疫史人群中,乙型肝炎病毒表面抗原(HbsAg)、抗-HBc (HbcAb)均阴性且抗-HBs<10 mIU/ml,以及最终完成加强免疫且有实验室结果者为研究对象,共322名。采用简单随机分组方法将322名研究对象随机分为2组,分别接种1剂市售的啤酒酵母HepB[以下简称HepB(酵母);151名]和基因重组HepB[以下简称HepB(CHO);171名],剂量均为20 μg。免疫后30 d采集静脉血5 ml,定量检测抗-HBs的几何平均浓度(GMC),观察加强免疫效果,采用多元线性回归和多因素logistic回归模型分析研究对象加强免疫后抗-HBs的GMC和阳转率的相关因素。 结果: 研究对象抗-HBs阳转率为82.61%(266名),GMC为(131.63±12.94)mIU/ml。加强免疫前抗-HBs<2.5和2.5~10 mIU/ml组加强免疫后抗-HBs阳转率分别为74.54%(161名)和99.06%(105名)(P<0.001);加强1剂HepB(CHO)后,抗-HBs阳转率高于加强1剂HepB(酵母),分别为87.13%(149名)和77.48%(117名)(P=0.023)。与接种HepB(酵母)相比,接种HepB(CHO)是加强免疫后抗体阳转的相关因素,OR(95%CI)值为1.91(1.02~3.56)(P=0.042);与加强免疫前抗-HBs<2.5 mIU/ml相比,加强前抗体水平2.5~10 mIU/ml是加强免疫后抗体阳转的相关因素,OR(95%CI)值为36.15(4.91~266.02)(P<0.001)。 结论: 研究对象接种1剂乙型肝炎疫苗有良好的免疫应答;加强免疫前抗-HBs水平和加强用疫苗种类是免疫应答的相关因素。.
引用
- Zhang XJ, Wu ZW, Zhang YH, et al. [The effect of booster dose vaccination 21- to 32-years after primary vaccination with hepatitis B vaccine in the population born from 1986 to 1996 in Zhengding County of Hebei Province]. Zhonghua Yu Fang Yi Xue Za Zhi. 2020. PMID: 32907282. doi:10.3760/cma.j.cn112150-20200509-00710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。